Nastassja K. Scheidegger

Nastassja K. Scheidegger

Auto-generated profile, based on publicly available information

Nastassja K. Scheidegger

Oncology department, University Children’s Hospital Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SLShan Lin
Shan Lin
CLClément Larrue
Clément Larrue
NSNastassja K. Scheidegger
Nastassja K. Scheidegger
BSBo Kyung A. Seong
Bo Kyung A. Seong
NDNeekesh V. Dharia
Neekesh V. Dharia
KSKimberly Stegmaier
Kimberly Stegmaier
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have been performed in vitro using established cell lines, evaluating the physiologic relevance of these targets is critical. We have established a CRISPR screening approach using orthotopic xenograft models to validate and prioritize AML-enriched dependencies in vivo, including in CRISPR-competent AML patient-derived xenograft (PDX) models tractable for genome editing. Our integrated pipeline has revealed several targets with translational value, including SLC5A3 as a metabolic vulnerability for AML addicted to exogenous myo-inositol and MARCH5 as a critical guardian to prevent apoptosis in AML. MARCH5 repression enhanced the efficacy of BCL2 inhibitors such as venetoclax, further highlighting the clinical potential of targeting MARCH5 in AML. Our study provides a valuable strategy for discovery and prioritization of new candidate AML therapeutic targets. Significance: There is an unmet need to improve the clinical outcome of AML. We developed an integrated in vivo screening approach to prioritize and validate AML dependencies with high translational potential. We identified SLC5A3 as a metabolic vulnerability and MARCH5 as a critical apoptosis regulator in AML, both of which represent novel therapeutic opportunities. This article is highlighted in the In This Issue feature, p. 275

19 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
STSelina Troester
Selina Troester
TEThomas Eder
Thomas Eder
NWNadja Wukowits
Nadja Wukowits
MPMartin Piontek
Martin Piontek
PFPablo Fernández-Pernas
Pablo Fernández-Pernas
FGFlorian Grebien
Florian Grebien
Nucleoporin 98 (NUP98) fusion oncoproteins are strong drivers of pediatric acute myeloid leukemia (AML) with poor prognosis. Here we show that NUP98 fusion-expressing AML harbors an epigenetic signature that is characterized by increased accessibility of hematopoietic stem cell genes and enrichment of activating histone marks. We employ an AML model for ligand-induced degradation of the NUP98::KDM5A fusion oncoprotein to identify epigenetic programs and transcriptional targets that are directly regulated by NUP98::KDM5A through CUT&Tag and nascent RNA-seq. Orthogonal genome-wide CRISPR/Cas9 screening identifies 12 direct NUP98::KDM5A target genes, which are essential for AML cell growth. Among these, we validate cyclin-dependent kinase 12 (CDK12) as a druggable vulnerability in NUP98::KDM5A-expressing AML. In line with its role in the transcription of DNA damage repair genes, small-molecule-mediated CDK12 inactivation causes increased DNA damage, leading to AML cell death. Altogether, we show that NUP98::KDM5A directly regulates a core set of essential target genes and reveal CDK12 as an actionable vulnerability in AML with oncogenic NUP98 fusions.

3 April 2023
Verified
Other
Open access
SLShan Lin
Shan Lin
CLClément Larrue
Clément Larrue
NSNastassja K. Scheidegger
Nastassja K. Scheidegger
BSBo Kyung A. Seong
Bo Kyung A. Seong
NDNeekesh V. Dharia
Neekesh V. Dharia
KSKimberly Stegmaier
Kimberly Stegmaier
Supplementary Tables from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

3 April 2023
Verified
Other
Open access
SLShan Lin
Shan Lin
CLClément Larrue
Clément Larrue
NSNastassja K. Scheidegger
Nastassja K. Scheidegger
BSBo Kyung A. Seong
Bo Kyung A. Seong
NDNeekesh V. Dharia
Neekesh V. Dharia
KSKimberly Stegmaier
Kimberly Stegmaier
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have been performed in vitro using established cell lines, evaluating the physiologic relevance of these targets is critical. We have established a CRISPR screening approach using orthotopic xenograft models to validate and prioritize AML-enriched dependencies in vivo, including in CRISPR-competent AML patient-derived xenograft (PDX) models tractable for genome editing. Our integrated pipeline has revealed several targets with translational value, including SLC5A3 as a metabolic vulnerability for AML addicted to exogenous myo-inositol and MARCH5 as a critical guardian to prevent apoptosis in AML. MARCH5 repression enhanced the efficacy of BCL2 inhibitors such as venetoclax, further highlighting the clinical potential of targeting MARCH5 in AML. Our study provides a valuable strategy for discovery and prioritization of new candidate AML therapeutic targets.Significance:There is an unmet need to improve the clinical outcome of AML. We developed an integrated in vivo screening approach to prioritize and validate AML dependencies with high translational potential. We identified SLC5A3 as a metabolic vulnerability and MARCH5 as a critical apoptosis regulator in AML, both of which represent novel therapeutic opportunities.This article is highlighted in the In This Issue feature, p. 275

3 April 2023
Verified
Other
Open access
SLShan Lin
Shan Lin
CLClément Larrue
Clément Larrue
NSNastassja K. Scheidegger
Nastassja K. Scheidegger
BSBo Kyung A. Seong
Bo Kyung A. Seong
NDNeekesh V. Dharia
Neekesh V. Dharia
KSKimberly Stegmaier
Kimberly Stegmaier
Supplementary Figures from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

9 December 2025
Verified
Other
Open access
SLShan Lin
Shan Lin
CLClément Larrue
Clément Larrue
NSNastassja K. Scheidegger
Nastassja K. Scheidegger
BSBo Kyung A. Seong
Bo Kyung A. Seong
NDNeekesh V. Dharia
Neekesh V. Dharia
KSKimberly Stegmaier
Kimberly Stegmaier
Supplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML